Literature DB >> 19571553

Clinical and molecular features of type 1 pseudohypoaldosteronism.

Felix G Riepe1.   

Abstract

Pseudohypoaldosteronism (PHA) is a rare heterogeneous syndrome of mineralocorticoid resistance causing insufficient potassium and hydrogen secretion. PHA type 1 (PHA1) causes neonatal salt loss, failure to thrive, dehydration and circulatory shock. Two different forms of PHA1 can be distinguished on the clinical and genetic level, showing either a systemic or a renal form of mineralocorticoid resistance. This review provides an overview on transepithelial sodium reabsorption and on clinical features and the underlying molecular pathology of systemic and renal PHA1 caused by mutations in the subunit genes (SCNN1A, SCNN1B, SCNN1G) of the epithelial sodium channel (ENaC) and the mineralocorticoid receptor coding gene NR3C2. The in vitro investigation of several mutants has resulted in important progress in the understanding of the physiology of ENaC and the mineralocorticoid receptor. Some mutations are discussed in more detail to demonstrate some of these findings. A better clinical work-up of the patients suffering from PHA1 may delineate additional associations between the genotype and phenotype in the future. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571553     DOI: 10.1159/000224334

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  32 in total

Review 1.  Genetic disorders of ion channels.

Authors:  Decha Enkvetchakul
Journal:  Mo Med       Date:  2010 Jul-Aug

2.  Ocular and skin manifestations in systemic pseudohypoaldosteronism.

Authors:  Mahmoud Salah Eliwa; Aymen Hussein El-Emmawie; Mahmood Ahmad Saeed
Journal:  BMJ Case Rep       Date:  2014-03-20

3.  Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.

Authors:  Edwige-Ludiwyne Hubert; Raphaël Teissier; Fábio L Fernandes-Rosa; Michel Fay; Marie-Edith Rafestin-Oblin; Xavier Jeunemaitre; Chantal Metz; Brigitte Escoubet; Maria-Christina Zennaro
Journal:  J Am Soc Nephrol       Date:  2011-09-08       Impact factor: 10.121

Review 4.  Recognizing genetic disease: A key aspect of pediatric pulmonary care.

Authors:  Lael M Yonker; Megan H Hawley; Peter P Moschovis; Mengdi Lu; T Bernard Kinane
Journal:  Pediatr Pulmonol       Date:  2020-07

5.  Genome-wide analysis of Pax8 binding provides new insights into thyroid functions.

Authors:  Sergio Ruiz-Llorente; Enrique Carrillo Santa de Pau; Ana Sastre-Perona; Cristina Montero-Conde; Gonzalo Gómez-López; James A Fagin; Alfonso Valencia; David G Pisano; Pilar Santisteban
Journal:  BMC Genomics       Date:  2012-04-24       Impact factor: 3.969

6.  A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene.

Authors:  Se Eun Lee; Yun Hye Jung; Kyoung Hee Han; Hyun Kyung Lee; Hee Gyung Kang; Il Soo Ha; Yong Choi; Hae Il Cheong
Journal:  Korean J Pediatr       Date:  2011-02-28

7.  Critical points in the management of pseudohypoaldosteronism type 1.

Authors:  Tülay Güran; Serpil Değirmenci; İpek K Bulut; Aysun Say; Felix G Riepe; Ömer Güran
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-06-08

8.  Autosomal dominant pseudohypoaldosteronism type 1 with a novel splice site mutation in MR gene.

Authors:  Kyoko Kanda; Kandai Nozu; Naoki Yokoyama; Ichiro Morioka; Akihiro Miwa; Yuya Hashimura; Hiroshi Kaito; Kazumoto Iijima; Masafumi Matsuo
Journal:  BMC Nephrol       Date:  2009-11-14       Impact factor: 2.388

9.  Novel SCNN1A gene splicing-site mutation causing autosomal recessive pseudohypoaldosteronism type 1 (PHA1) in two Italian patients belonging to the same small town.

Authors:  Gregorio Serra; Vincenzo Antona; Maria Michela D'Alessandro; Maria Cristina Maggio; Vincenzo Verde; Giovanni Corsello
Journal:  Ital J Pediatr       Date:  2021-06-16       Impact factor: 2.638

10.  Novel mutations in the SCNN1A gene causing Pseudohypoaldosteronism type 1.

Authors:  Jian Wang; Tingting Yu; Lei Yin; Jing Li; Li Yu; Ye Shen; Yongguo Yu; Yongnian Shen; Qihua Fu
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.